Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 402481, 10 pages
http://dx.doi.org/10.1155/2015/402481
Research Article

Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels

1Department of Emergency, Weifang People’s Hospital, Weifang 261041, China
2Department of Cardiology, Linyi People’s Hospital, Linyi 276003, China
3Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

Received 25 September 2014; Revised 16 December 2014; Accepted 16 December 2014

Academic Editor: Bas J. D. Boukens

Copyright © 2015 Fang-Cheng Su et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. D. McManus, V. Xanthakis, L. M. Sullivan et al., “Longitudinal tracking of left atrial diameter over the adult life course: clinical correlates in the community,” Circulation, vol. 121, no. 5, pp. 667–674, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. J. P. Piccini, B. G. Hammill, M. F. Sinner et al., “Incidence and prevalence of atrial fibrillation and associated mortality among medicare beneficiaries: 1993–2007,” Circulation: Cardiovascular Quality and Outcomes, vol. 5, no. 1, pp. 85–93, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Hansson, B. Madsen-Härdig, and S. B. Olsson, “Arrhythmia-provoking factors and symptoms at the onset of paroxysmal atrial fibrillation: a study based on interviews with 100 patients seeking hospital assistance,” BMC Cardiovascular Disorders, vol. 4, article 13, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Nishi, T. Sakaguchi, S. Miyagawa et al., “Impact of microRNA expression in human atrial tissue in patients with atrial fibrillation undergoing cardiac surgery,” PLoS ONE, vol. 8, no. 9, Article ID e73397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. V. L. Roger, A. S. Go, D. M. Lloyd-Jones et al., “Heart disease and stroke statistics—2012 update: a report from the American Heart Association,” Circulation, vol. 125, no. 1, pp. e2–e220, 2012. View at Publisher · View at Google Scholar
  6. P. N. Jensen, E. L. Thacker, S. Dublin, B. M. Psaty, and S. R. Heckbert, “Racial differences in the incidence of and risk factors for atrial fibrillation in older adults: the cardiovascular health study,” Journal of the American Geriatrics Society, vol. 61, no. 2, pp. 276–280, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. D. Li, B. P. Tang, F. Guo et al., “Effect of atorvastatin on left atrial function of patients with paroxysmal atrial fibrillation,” Genetics and Molecular Research, vol. 12, no. 3, pp. 3488–3494, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Alonso, B. P. Krijthe, T. Aspelund et al., “Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium,” Journal of the American Heart Association, vol. 2, no. 2, Article ID e000102, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Naji, D. Suran, V. Kanic, D. Vokac, and M. Sabovic, “Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion,” International Heart Journal, vol. 50, no. 2, pp. 153–160, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Ozaydin, E. Varol, S. M. Aslan et al., “Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion,” American Journal of Cardiology, vol. 97, no. 10, pp. 1490–1493, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M.-F. Demierre, P. D. R. Higgins, S. B. Gruber, E. Hawk, and S. M. Lippman, “Statins and cancer prevention,” Nature Reviews Cancer, vol. 5, no. 12, pp. 930–942, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. van de Ree, M. V. Huisman, H. M. G. Princen et al., “Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus,” Atherosclerosis, vol. 166, no. 1, pp. 129–135, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. T. W. Du Clos and C. Mold, “C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity,” Immunologic Research, vol. 30, no. 3, pp. 261–277, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Black, I. Kushner, and D. Samols, “C-reactive protein,” Journal of Biological Chemistry, vol. 279, no. 47, pp. 48487–48490, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Tamargo, R. Caballero, and E. Delpón, “Pharmacological approaches in the treatment of atrial fibrillation,” Current Medicinal Chemistry, vol. 11, no. 1, pp. 13–28, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Fuster, L. E. Ryden, D. S. Cannom et al., “ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society,” Europace, vol. 8, pp. 651–745, 2006. View at Google Scholar
  17. J. L. Anderson, C. A. A. Maycock, D. L. Lappé et al., “Frequency of elevation of C-reactive protein in atrial fibrillation,” The American Journal of Cardiology, vol. 94, no. 10, pp. 1255–1259, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. K. Jain and P. M. Ridker, “Anti-inflammatory effects of statins: clinical evidence and basic mechanisms,” Nature Reviews Drug Discovery, vol. 4, no. 12, pp. 977–987, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Holm, A. K. Andreassen, T. Ueland et al., “Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients,” The American Journal of Cardiology, vol. 87, no. 6, pp. 815–818, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Kumagai, H. Nakashima, and K. Saku, “The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model,” Cardiovascular Research, vol. 62, no. 1, pp. 105–111, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Demir, I. Can, F. Koc et al., “Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy,” Medical Principles and Practice, vol. 20, no. 5, pp. 464–469, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. F. Zhuo, B. S. Huang, Y. Chen et al., “Influence of atorvastatin treatment on the inflammatory biomarkers YKL-40 and hsCRP in patients with atrial fibrillation,” New Medicine, vol. 44, pp. 169–172, 2013. View at Google Scholar
  23. Z. X. Guo, “Effect and mechanisms of atorvastatin on paroxysmal atrial fibrillation in patients with hypertension,” Journal of Taishan Medical College, vol. 32, pp. 186–188, 2011. View at Google Scholar
  24. A. J. Camm, G. Y. Lip, R. de Caterina et al., “2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association,” European Heart Journal, vol. 33, no. 21, pp. 2719–2747, 2012. View at Publisher · View at Google Scholar
  25. Y. X. Wang, F. J. Liu, and X. Q. Li, “The association study of atorvastatin intensive treatment to hypertension with PAF,” Modern Medicine Journal of China, vol. 13, pp. 37–39, 2011. View at Google Scholar
  26. J. Y. Dong, H. T. Liu, C. Jin, P. Zhang, and W. Liu, “Effect of lipitor on CRP, IL-8 and Et in patients with hypertension and atrial fibrillation,” China Modern Medicine, vol. 16, pp. 46–47, 2009. View at Google Scholar
  27. Z. B. Yuan, “Effect of statins on inflammatory markers and thromboxane in patients with hypertension and atrial fibrillation,” Journal of Clinical and Experimental Medicine, vol. 7, pp. 86–87, 2008. View at Google Scholar
  28. A. Stang, “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses,” European Journal of Epidemiology, vol. 25, no. 9, pp. 603–605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. P. F. Whiting, M. E. Weswood, A. W. S. Rutjes, J. B. Reitsma, P. N. M. Bossuyt, and J. Kleijnen, “Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies,” BMC Medical Research Methodology, vol. 6, article 9, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Jackson, I. R. White, and R. D. Riley, “Quantifying the impact of between-study heterogeneity in multivariate meta-analyses,” Statistics in Medicine, vol. 31, no. 29, pp. 3805–3820, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. J. L. Peters, A. J. Sutton, D. R. Jones, K. R. Abrams, and L. Rushton, “Comparison of two methods to detect publication bias in meta-analysis,” The Journal of the American Medical Association, vol. 295, no. 6, pp. 676–680, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Zintzaras and J. P. A. Ioannidis, “HEGESMA: genome search meta-analysis and heterogeneity testing,” Bioinformatics, vol. 21, no. 18, pp. 3672–3673, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Zhu, A. Q. Ma, L. Yang, and X. M. Dang, “Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway,” International Journal of Molecular Sciences, vol. 14, no. 12, pp. 24476–24491, 2013. View at Publisher · View at Google Scholar
  34. J. K. Liao, “Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol,” The American Journal of Cardiology, vol. 96, no. 5, pp. 24F–33F, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. A. Oliveira, M. I. Yoshida, V. J. Belinelo, and R. S. Valotto, “Degradation kinetics of atorvastatin under stress conditions and chemical analysis by HPLC,” Molecules, vol. 18, no. 2, pp. 1447–1456, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Mohammed, L. Qian, N. B. Janakiram, S. Lightfoot, V. E. Steele, and C. V. Rao, “Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice,” International Journal of Cancer, vol. 131, no. 8, pp. 1951–1962, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Zheng, X.-X. Cui, Z. Gao et al., “Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence,” Cancer Prevention Research, vol. 3, no. 1, pp. 114–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Chen, H. Bi, J. Hou et al., “Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells,” Cell Death & Disease, vol. 4, no. 9, article e814, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. O. Abaci, C. Kocas, V. Oktay et al., “Comparison of rosuvastatin versus atorvastatin for preventing postoperative atrial fibrillation,” Heart Surgery Forum, vol. 16, no. 3, pp. E158–E161, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Gelosa, M. Cimino, A. Pignieri, E. Tremoli, U. Guerrini, and L. Sironi, “The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation,” Vascular Health and Risk Management, vol. 3, no. 5, pp. 567–577, 2007. View at Google Scholar · View at Scopus
  41. N. Höglund, J. Andersson, H. Almroth et al., “The predictive value of C-reactive protein on recurrence of atrial fibrillation after cardioversion with or without treatment with atorvastatin,” International Journal of Cardiology, vol. 167, no. 5, pp. 2088–2091, 2013. View at Publisher · View at Google Scholar · View at Scopus